Core Viewpoint - Fluor Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its business prospects and financial guidance during the class period from February 28, 2025, to July 31, 2025 [1][3]. Allegations - The lawsuit claims that Fluor failed to disclose increasing costs associated with major projects, including the Gordie Howe International Bridge and I-635/LBJ, due to subcontractor design errors, price increases, and scheduling delays [3]. - It is alleged that these issues, along with reduced capital spending by customers and economic uncertainty, significantly impacted Fluor's business and financial results [3]. - The company's financial guidance for FY 2025 was deemed unreliable, with overstated risk mitigation strategies and understated impacts of economic uncertainty [3]. Financial Results - On August 1, 2025, Fluor reported disappointing Q2 2025 financial results, attributing them to rising costs in infrastructure projects and reduced customer spending [4]. - The adjusted EBITDA guidance was revised down to $475 million to $525 million from a previous range of $575 million to $675 million, and adjusted EPS was lowered to $1.95 to $2.15 from $2.25 to $2.75 [4]. - Following these disclosures, Fluor's stock price dropped by $15.35 per share, or 27.04%, closing at $41.42 per share [4]. Next Steps - Shareholders may participate in the class action against Fluor, with a deadline to submit lead plaintiff papers by November 14, 2025 [5]. - Shareholders can choose to remain absent class members without participating in the case [5].

Core Viewpoint - Cytokinetics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the timeline for the New Drug Application (NDA) submission and approval process for its drug aficamten [2][3]. Group 1: Company Overview - Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for treating diseases that compromise muscle performance [1]. Group 2: Legal Allegations - The class action was filed on behalf of shareholders who purchased Cytokinetics securities between December 27, 2023, and May 6, 2025, claiming that the company misled them about the NDA submission timeline for aficamten [2]. - The complaint states that during the class period, Cytokinetics made materially false statements regarding the expected FDA approval for aficamten, which was anticipated in the second half of 2025, and failed to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [3]. Group 3: Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers by November 17, 2025, to serve as lead plaintiff, representing other class members in the litigation [4].

Core Viewpoint - Jasper Therapeutics, a clinical-stage biotechnology company, is facing a class action lawsuit due to allegations of misleading investors about the commercial prospects of its lead product candidate, briquilimab [1][2]. Allegations - The lawsuit claims that Jasper failed to disclose critical information regarding its manufacturing processes, specifically that it lacked the necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations [2]. - This failure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including briquilimab [2]. - The situation heightened the likelihood of disruptive cost-reduction measures, leading to an overstatement of the company's business and financial prospects, as well as briquilimab's clinical and commercial potential [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Evolv Technologies Holdings, Inc. due to a class action complaint related to alleged breaches of fiduciary duties by the company's board of directors [1][2]. Summary by Sections Company Overview - Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) is facing legal scrutiny following a class action complaint filed on November 1, 2024, concerning its financial disclosures from August 19, 2022, to October 30, 2024 [1]. Financial Misstatements - The complaint alleges that Evolv's financial statements from Q2 2022 to Q2 2024 contain material misstatements affecting revenue recognition and other metrics. The company disclosed that certain sales were subject to undisclosed terms and that misconduct occurred among its personnel [2]. Stock Price Impact - Following the announcement of these issues on October 25, 2024, Evolv's stock price plummeted approximately 40%, dropping from $4.10 per share to $2.47 per share [2]. Next Steps for Investors - Long-term stockholders of Evolv are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims related to the company's financial issues [3]. Law Firm Background - Bragar Eagel & Squire, P.C. is a recognized law firm specializing in representing investors in complex litigation across various courts in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against WPP PLC, alleging that the company misled investors about its business prospects during the class period from February 27, 2025, to July 8, 2025 [1]. Allegations - The complaint claims that WPP's management created a false impression of having reliable information regarding projected revenue and growth, while downplaying risks associated with seasonality and macroeconomic fluctuations [3]. - It is alleged that WPP's optimistic reports on client acquisition and retention were misleading, as the company's media division was losing market share and was not effectively competitive [3]. Impact of Trading Update - On July 9, 2025, WPP issued a trading update indicating a deterioration in performance, attributing this to macroeconomic uncertainties affecting client spending and weaker new business than expected, partly due to ongoing restructuring within WPP Media (GroupM) [4]. - Following this announcement, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking a decline of approximately 18.1% [4].

Core Viewpoint - Marex Group PLC is facing a class action lawsuit for allegedly misleading investors about its revenue projections and inflating its financial metrics through improper accounting practices [2][3]. Group 1: Company Overview - Marex Group PLC is a U.K.-based diversified global financial services platform listed on NASDAQ under the ticker MRX [1]. Group 2: Legal Allegations - The lawsuit claims that Marex Group failed to disclose that it improperly inflated its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [3]. - As a result of these alleged actions, investors who sold short Marex Group securities during the class period have reportedly suffered significant losses [2][3]. Group 3: Class Action Details - The class period for the lawsuit is defined as August 14, 2024, to August 5, 2025 [2]. - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by December 8, 2025 [4]. - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [2][3]. Allegations - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were allegedly materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, regarding the suspension of all new Novum LVP sales, Baxter's stock price dropped by 22.4%, closing at $21.76 [3]. Class Action Participation - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [4].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against MGP Ingredients, Inc. (MGPI) on behalf of long-term stockholders due to a class action complaint filed on December 16, 2024, concerning alleged breaches of fiduciary duties by the board of directors during the class period from May 4, 2023, to October 30, 2024 [1][6]. Company Overview - MGP Ingredients, Inc. is a manufacturer of hard liquors, including tequila, bourbon, rye, whiskey, vodka, and gin, selling products under its own brands and to other distributors [6]. - Prior to the class period, sales of hard liquors surged due to COVID-19, but post-quarantine, the industry experienced a slowdown, leading to increased inventory backlogs [6]. Allegations and Impact - The complaint alleges that MGPI misled investors by assuring them that it was well-positioned to manage the industry slowdown and inventory buildup [6]. - On October 17, 2024, MGPI announced that demand had slowed and excess inventory would negatively impact sales, resulting in a 29.5% drop in stock price [6]. - Following further revelations on October 31, 2024, regarding the greater-than-expected impact of excess inventory, MGPI's stock fell an additional 14.7%, closing at $49.04 per share, leading to a total decline of nearly 50% and significant loss in market capitalization [6].

Core Viewpoint - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. for allegedly misleading investors regarding its business operations and the quality of care provided at its facilities [1][2]. Allegations - The lawsuit claims that the registration statement related to KinderCare's October 2024 IPO was false and misleading, failing to disclose several critical issues [3]. - Specific allegations include numerous incidents of child abuse, neglect, and harm at KinderCare facilities [3]. - It is asserted that KinderCare did not provide the "highest quality care possible" and often failed to meet basic care standards and comply with relevant laws and regulations [3]. - As a result of these issues, KinderCare is said to be exposed to significant undisclosed risks, including potential lawsuits, regulatory actions, negative publicity, reputational damage, and business losses [3]. Legal Proceedings - Investors interested in participating in the class action must file their motions with the court by October 14, 2025, to serve as lead plaintiffs [4]. - Shareholders can choose to remain absent class members without participating in the case while still being eligible for recovery [4]. Rosen Law Firm - Rosen Law Firm is noted for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who sold short Marex Group PLC securities, alleging that the company misled investors regarding its revenue projections and inflated its financial metrics through improper accounting practices [1][2]. Group 1: Allegations Against Marex Group PLC - The lawsuit claims that Marex Group PLC failed to disclose that it improperly inflated its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these alleged misrepresentations, class members have reportedly suffered significant losses and damages [2]. Group 2: Class Action Participation - Investors who sold short Marex Group PLC securities between August 14, 2024, and August 5, 2025, may be eligible to participate in the class action [1]. - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by December 8, 2025 [3]. - Participation in the case is not required to be eligible for recovery; investors can remain absent class members if they choose not to take action [3]. Group 3: About Robbins LLP - Robbins LLP is recognized as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].